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Abstract Hypertension is a major, if not the most important,
contributor to the disease burden and premature death globally
which is largely related to cardiovascular disease. In both the
primary and the secondary preventions of cardiovascular dis-
ease, blood pressure (BP) targets are often not achieved which
is similar to achievement of cholesterol goals. Combining as-
pirin, cholesterol and blood pressure-lowering agents into a
fixed-dose combination pill called the cardiovascular polypill
has been proposed as complementary care in the prevention of
cardiovascular diseases in both the primary and secondary
preventions of cardiovascular disease. This review article fo-
cuses on the potential role of fixed-dose combination therapy
in the treatment of hypertension, outlines the pros and cons of
combination therapy and emphasizes the rationale for trialling
their use. Current and planned future cardiovascular polypill
trials are summarized, and the prerequisites for implementa-
tion of the polypill strategy are described.
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Introduction
Hypertension is a major, if not the most important, contributor
to the disease burden and premature death globally which is
largely related to cardiovascular disease [1]. In the last de-
cades, the number of individuals with uncontrolled hyperten-
sion has increased to approximately one billion [2]. Even
among identified and treated individuals, a large part of them
fail to reach currently recommended blood pressure (BP) tar-
gets in high-income countries [3]. The majority of these indi-
viduals have mild hypertension (grade I) without manifest
vascular disease [4]. However, risk factors for cardiovascular
disease such as hypertension, dyslipidaemia, obesity and in-
sulin resistance tend to cluster, leaving these individuals prone
to develop cardiovascular disease [5]. In the Western world,
cardiovascular disease affects half of all individuals over their
lifetimes [6]. More strikingly, the burden of cardiovascular
disease is increasing disproportionally in low- and middle-
income countries (LMICs), in which over 80 % of the global
cardiovascular deaths occur [7, 8]. In those affected by cardio-
vascular disease, risk factors such as hypertension modify the
risk of recurrence of a major cardiovascular event. Although
rates of hypertension awareness and treatment have improved
over the past few decades, control of BP in secondary preven-
tion has similar limited success as in primary prevention.
Comparable results have been seen for other risk factors such
as dyslipidaemia [9•]. To call a halt to the growing incidence
of cardiovascular disease will require addressing the societal
determinants of the root causes of cardiovascular disease, the
development of risk factors among individuals and the multi-
factorial use of medication to treat hypertension and other
cardiovascular risk factors simultaneously [10]. A multidrug
fixed-dose combination pill might be a useful tool against
cardiovascular disease. This article aims to review a potential
role for the polypill in the treatment of hypertension.
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Multidrug Treatment for Blood Pressure Reduction
BP-lowering therapy is one of the cornerstones of the preven-
tion of cardiovascular disease as it reduces the risk of cardio-
vascular disease largely. A reduction of 10 mmHg systolic BP
has been shown to lower the risk of coronary events by 20 %
and of cerebrovascular events by 45 % in those without car-
diovascular disease. Similarly, in secondary prevention, the
risk of a recurrent coronary event is reduced by approximately
25 % and recurrent cerebrovascular event by 35 % per
10 mmHg systolic BP [11]. A single BP-lowering agent in a
standard dose, in general, reduces the systolic BP by 8 to
10 mmHg. The effect is largest in those with higher pretreat-
ment BP levels [12].
Strategies to improve BP control include the prompt shift
from monotherapy to multidrug therapy [13]. In most individ-
uals with hypertension, combining BP-lowering drugs is nec-
essary to achieve adequate BP reductions. The rationale of
combination therapy lies in an additive BP reduction when
combining various classes of BP-lowering agents [12, 14].
Furthermore, multidrug therapies in a low therapeutic dose
are generally better tolerated than respective monotherapies
in higher dose for obtaining similar BP reductions.
Accordingly, recent guidelines advocate multidrug therapy
with a combination of two BP-lowering agents as an initial
therapy for the majority of hypertensive patients even though
this is known to be associated with diminishing adherence and
inadequate prescription [15, 16]. If provided in a single pill, in
addition to the potential synergistic actions, a multidrug strat-
egy might improve patients’ adherence to medication by re-
ducing pill burden and dosing frequency [17, 18]. European
guidelines even suggest fixed-dose combinations of BP-
lowering drugs over separate BP-lowering agents due to the
additional benefits on adherence [15]. Therefore, fixed-dose
combination (FDC) pills are well accepted in the treatment of
hypertension.
Multifactorial, Multidrug Treatment for Risk
Reduction
BP-lowering therapy is one of the cornerstones of the preven-
tion of cardiovascular disease. Additionally, anti-platelet and
cholesterol-lowering therapy reduce the risk of cardiovascular
events. Combining these agents into a single pill has been
suggested many years ago. The concept of ‘aspolol’ (aspirin
and atenolol) was first discussed in the 1970s (R. Peto, per-
sonal communication), and patents for multidrug combination
pills began to be lodged in the late 1990s [19, 20]. The first
major scientific meeting on this concept was held in 2001,
when the World Health Organization and the Wellcome
Trust initiated a meeting of experts to discuss evidence-
based and affordable interventions for non-communicable
diseases [21]. The term ‘polypill’ was introduced with the
publication ofWald and Law’s papers in 2003. They proposed
a strategy in which everyone aged 55 and older and everyone
with existing cardiovascular disease would be treated with a
single pill containing folic acid, aspirin, a statin and three low-
dosed BP-lowering agents. By simultaneously addressing
multiple cardiovascular risk factors in a low-risk population,
regardless of pretreatment levels, the risk of major cardiovas-
cular events could be reduced tremendously [22]. Instantly,
large resistance arose as the lifetime use of drugs in a popula-
tion at a low absolute risk of cardiovascular disease would
largely promote unnecessary medicalization, adverse events
and inducing a sense of protection, thereby deflecting atten-
tion from healthy behaviours. Even though combining multi-
ple well-established cardiovascular drugs into a single polypill
might result in a significant reduction of cardiovascular events
in a low-risk population, this strategy is not likely to be im-
plemented in the next decade as it would require a paradigm
shift of preventive care.
Nonetheless, the concept of a multifactorial, multidrug ap-
proach regardless of pretreatment risk factor levels to reduce
the risk of cardiovascular disease could be applied to popula-
tions at increased risk of cardiovascular disease, such as pa-
tients with hypertension or established cardiovascular disease.
Among people without established cardiovascular disease,
there has been a transition in recent decades from treatment
recommendations for BP-lowering therapy and statins being
based on single risk factors, e.g. BP thresholds, to treatment
based on a predicted absolute risk of cardiovascular disease
[23]. In these patients, multiple drugs generally are indicated
and the margin of benefit is high. Regardless of initial low-
density lipoprotein (LDL) cholesterol, prescribing a statin re-
duces the risk of a future event [24]. The reduction of LDL
cholesterol is proportional to the clinical benefits [11, 25].
Similarly, for patients with mainly dyslipidaemia, most recent
data from the SPRINT trial suggested that intensive BP with
lower treatment goals in non-diabetic patients reduces the risk
of cardiovascular disease even further [26•]. The use of aspirin
in primary prevention is still under debate and is generally not
recommended, although recent evidence, demonstrating a po-
tential reduction in cancer deaths with long-term use, might
change the risk/benefit equation [27, 28].
Regardless of the exact components of polypills, an FDC
pill could be considered as a multifactorial baseline therapy
providing the minimum standard therapy for moderate- to
high-risk individuals with additional benefits on adherence.
The principal goal of a polypill strategy would be reducing
the risk of major cardiovascular events and mortality, and not
necessarily normalizing risk factors or reaching treatment
goals. However, this strategy does not rule out tailored care
as every individual can be treated with additional BP- and/or
cholesterol-lowering agents if the treatment goals are not
achieved.
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Similar to FDC pills with solely BP-lowering agents, im-
provement of adherence in patients at risk of cardiovascular
disease is an important principle of the polypill concept. Long-
term adherence is low, with only 45 % adherence to BP-
lowering therapy and statin use after 12 months [29].
Combination pills have been shown to increase this adherence
by reducing the number of pills and providing simplicity in the
treatment [30].
Another major advantage of a polypill with major conse-
quences on accessibility to healthcare in developing countries
relates to the low costs and improved affordability. By dis-
pensing a single generic pill with multiple BP-lowering agents
and a statin for hypertension instead of the individual drugs,
packaging, dispensing and pharmacy expenditure can be re-
duced enormously. Hence, the concept of the polypill was
proposed as a simple, innovative and cost-effective public
health strategy to influence accessibility to medications and
adherence to treatment at a global scale.
There are also certain drawbacks to an FDC pill, meaning
that a polypill strategy cannot be applied in every individual.
Due to fixed combinations in a single pill, there is no flexibil-
ity in being able to change the class of BP-lowering drugs due
to contraindications or unacceptable adverse effects. In partic-
ular, patients with primarily hypertension might cease using
an FDC pill with BP-lowering agents due to statin-associated
myalgia. These issues might be addressed in the future by the
marketing of several FDC pills with various components,
thereby giving the clinician greater choice of drug class whilst
retaining the convenience of a polypill. In addition, FDC pills
with two, three or four BP-lowering agents and a statin might
be formulated for hypertensive patients in order to limit the
number of pills whilst achieving BP goals.
Clinical Evidence of FDC Pills
FDC formulations correspond closely to combinations that are
already in widespread use, such as an ACE inhibitor, thiazide
diuretic, beta-blocker and statin. The generic drugs used as
components of an FDC pill have been marketed for many
years in the prevention of cardiovascular disease in both pri-
mary and secondary preventions. It may very well be that
many patients use the identical components as a polypill ad-
ministered at the same time, although not in a single pill or
capsule. However, substantially different from when using an
FDC, each of the individual components in standard clinical
practice is generally prescribed at the discretion of the treating
physician for a specific indication and taking into account
relative contraindications. The concept of the polypill includes
promoting a widespread use of multifactorial cardiovascular
risk-lowering treatments regardless of risk factor levels which
need to demonstrate beneficial effects in trials.
One of the first clinical trials was a randomized, double-
blind, placebo-controlled trial in Iran. A total of 475 low-risk
participants without cardiovascular disease or cardiovascular
risk factors, aged 50 to 79 years, were randomized to an FDC
pill (aspirin 81 mg, enalapril 2.5 mg, hydrochlorothiazide
12.5 mg and atorvastatin 20 mg) or placebo for a period of
12 months. The trial showed that the FDC achieved modest
reductions of BP when treating a baseline systolic BP of
125 mmHg (mean difference systolic 4.5 mmHg and diastolic
1.6 mmHg) and LDL cholesterol (baseline LDL cholesterol
3.0 mmol/L, mean difference 0.46 mmol/L) even though the
FDC pill was well tolerated [31].
In addition, in the randomized, double-blind, placebo-
controlled ‘Programme to Improve Life and Longevity’
(PILLpilot) trial, 378 individuals at intermediate risk of car-
diovascular disease were randomized to using an FDC (aspirin
75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and
simvastatin 20 mg) or placebo during 12 weeks. The baseline
systolic BP was 134 mmHg and the LDL cholesterol was
3.7 mmol/L. Using the polypill resulted in a 10 mmHg
(95 % CI 8 to 12) lower mean systolic BP and 0.9 mmol/L
(95 %CI 0.8 to 1.0) lower mean LDL cholesterol compared to
using placebo [32]. The effect of the polypill on risk factor
levels was modified by the baseline levels of these risk factors,
resulting in the largest BP reduction in those with hyperten-
sion. The achieved cardiovascular relative risk reduction was
only modestly modified by the baseline levels of these risk
factors. Although mild adverse events such as cough and hy-
potension were reported more often in the polypill group,
these were not related to baseline risk factor levels, suggesting
that patients with mildly increased risk factor levels, but an
overall raised cardiovascular risk, would also benefit from
being treated with a polypill [33].
Recently, a dosage study has been performed in which the
polycap (aspirin 100 mg, atenolol 50 mg, hydrochlorothiazide
12.5 mg, ramipril 5 mg and simvastatin 20 mg) was used in
patients with a baseline systolic BP of 144 mmHg and LDL
cholesterol of 2.4 mmol/L. ‘The Second Indian Polycap Study’
(TIPS-2) with 518 patients demonstrated that a double-dosed
polycap with potassium supplementation resulted in a systolic
BP reduction of 17.4 mmHgwhich was a 2.8 mmHg additional
systolic BP reduction compared to a single-dosed polycap. The
LDL cholesterol was only 0.3 mmol/L decreased by using a
double-dosed polycap versus 0.1 mmol/L when using a single
polypill. It should be noted that at baseline, most patients al-
ready used a statin. Both treatments had similar discontinuation
rates (7.8 % in the double-dosed group versus 6.9 % in the
single-dosed group), suggesting also a potential role for various
dosed FDC pills [34].
As one of the most fundamental evidence are comparative
clinical studies of a polypill-based treatment strategy versus
reference treatment, these are necessary in order to put into
perspective the improvement obtained with a polypill-based
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treatment strategy compared to usual care. Only confirmatory
trials are able to show the net effect of the various hypothe-
sized benefits of a polypill in a real-life population. The ac-
ceptability, efficacy and economic impact of a polypill-based
strategy for the prevention of cardiovascular events are likely
to vary substantially between countries, and these will be
greatly influenced by the existing health-care systems i.e. usu-
al care and the subsidies offered for drug therapy. Hence,
information about these health-care system parameters for
implementing a polypill-based strategy from both developed
and developing countries in high-risk patients is imperative. It
could be hypothesized that implementation of the polypill
strategy would be most beneficial in LMICs.
A large international initiative to address the effects of
polypill versus usual care was undertaken by the ‘Single Pill
to Avert Cardiovascular Events’ (SPACE) Collaboration. The
Collaboration was initiated in 2009 and comprises a group of
academic investigators from Australia, New Zealand, India,
China, South Africa, Brazil, Canada, the UK, Ireland and the
Netherlands. Currently, three trials with similar design have
been published [30, 35, 36]. Each trial is as similar to real life
as possible within each national setting, whilst maintaining as
much uniformity between all trials as possible to facilitate the
final pooling of data. The ‘Use of aMultidrug Pill In Reducing
cardiovascular Events’ (UMPIRE) trial was the first random-
ized, clinical trial comparing a polypill-based treatment strat-
egy for the delivery of medication (aspirin, two BP-lowering
agents and a statin) to usual care among participants with
established cardiovascular disease or at equivalent high risk
(an estimated 5-year cardiovascular risk of ≥15 %, e.g. hyper-
tensive patients) in India and three European countries (the
UK, Ireland and the Netherlands). In the FDC group, physi-
cians could use a polypill that contained aspirin 75 mg, sim-
vastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or
hydrochlorothiazide 12.5 mg. In the usual care group, treat-
ment continued according to the physicians’ discretion. In
total, 2004 participants were randomized in India and
Europe. After a median follow-up of 15 months, the polypill
group showed to have an improved adherence (relative risk of
being adherent 1.33; 95 % CI 1.26 to 1.41) with a concurrent
2.6 mmHg (95 % CI 1.1 to 4.0) lower mean clinic systolic BP
and 0.11 mmol/L (95 % CI 0.05 to 0.17) lower mean LDL
cholesterol compared to the usual care group [30]. The size of
these benefits was regarded as modest in the relatively well-
treated high-risk population. As participants were randomized
to continuing usual care or a polypill, the consequences of
switching to a polypill were likely to be influenced by medi-
cations and doses used at baseline [30]. In the ‘IMProving
Adherence using Combination Therapy’ (IMPACT) trial,
513 patients in New Zealand were randomized to an FDC-
based care or usual care, similar to the UMPIRE trial. In this
trial, there was no statistically significant improvement in sys-
tolic BP (mean difference −2.2 mm Hg; 95 % CI −5.6 to 1.2)
or in LDL cholesterol (mean difference −0.05 mmol/L; 95 %
CI −0.17 to 0.08) after 12 months of treatment with the
polypill or usual care [35]. In the ‘Kanyini-Guidelines
Adherence with the Polypill’ (GAP) trial, 623 Australian pa-
tients were included. After a median of 18 months, the
polypill-based strategy did not show a differences in systolic
BP (mean difference −1.5 mmHg; 95 % CI −4.0 to 1.0) or
total cholesterol (mean difference 0.08 mmol/L; 95 % CI
−0.06 to 0.22) [36].
Data of these three trials have been combined into a pro-
spective, individual participant data meta-analysis. Compared
to usual care, participants with the FDC pill had higher adher-
ence to combination treatment (relative risk 1.58; 95 % CI
1.32 to 1.90), a 2.5 mmHg (95 % CI 0.4 to 4.5) lower systolic
BP and 0.1 mmol/L (95 % CI 0.0 to 0.2) lower LDL choles-
terol. Furthermore, baseline treatment levels were a major ef-
fect modifier for adherence and systolic BP with greatest im-
provements seen among those under-treated at baseline [37•].
Marketing the Polypill
Licensing is an essential step for marketing combination thera-
py in any population. Regulatory agencies are faced with new
issues when evaluating novel FDC formulations. The US Food
and Drug Administration (FDA) and the European Medicines
Agency (EMA) have approved various two-, and a couple of
three-drug combinations, but neither have granted a marketing
license for four- or five-drug formulations. Additionally, previ-
ous combination treatments only addressed one risk factor, i.e.
hypertension, complicating decision-making as in the polypill
concept, multiple risk factors are addressed simultaneously, ir-
respective of risk factor levels. Currently, effects of FDC for-
mulations have been shown in various comparative trials
powered on risk factors. Although the emerging opinion sug-
gests that cardiovascular endpoint trial studies are not required,
this is not yet undoubtedly adopted by the regulators. Treatment
effects on established surrogate endpoints that are reasonably
likely to predict clinical benefit, such as LDL cholesterol and
systolic BP, may result in marketing authorization [38].
Focus on High-Risk Patients
Given the present data on the effect of a polypill in moderate- to
high-risk patients, it is highly likely that a polypill-based treat-
ment strategy will be adopted in the forthcoming years.
Especially in LMICs, a polypill is, in general, the best alternative
treatment compared to hardly any treatment. Yet, similar in the
Western countries, the polypill has shown to have beneficial
effects on adherence and cardiovascular risk factor levels, indi-
cating a role for the polypill as a complementary treatment strat-
egy in the prevention of cardiovascular disease. However, if FDC
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formulations are licensed and a polypill-based treatment strategy
is to be successfully implemented, health-care professionals will
need to be convinced of the benefits of this approach. In general,
patients largely prefer using a polypill over usual care [39].
Currently, only one polypill has been marketed [40•].
Reservations for a Low-Risk Population
There is a theoretical rationale for a polypill-based treatment
in a low-risk population, in which imperfect and expensive
screening is avoided. Whilst the low-risk population has a
small absolute risk of cardiovascular events, this population
includes most of those who will experience cardiovascular
events due to the great size of a low-risk group [22].
Additionally, with the present increasing incidence of cardio-
vascular disease, there would be insufficient physicians and
health-care workers worldwide to screen and treat every indi-
vidual at risk. Instead of aiming lifestyle first and pharmaceu-
tical treatment only if required, a multifactorial approach to
prevent and treat cardiovascular diseases is far more efficient.
Although lifestyle modification is natural and safe, it is gen-
erally not low-cost, not simple and not sustainable [41]. Yet,
even a decade since the introduction of the concept, there
appears to be little support for a polypill-based preventive
strategy in a low-risk population. Possibly, if trials involving
moderate- and high-risk individuals show clear beneficial ef-
fects, the idea of offering treatment to everybody older than
50 years might raise widespread interest.
Some trials have been initiated in a low-risk population with
regard to risk factor reductions [31, 42]. Nevertheless, licensing
a polypill for a low-risk population will undoubtedly require
large clinical endpoint trials. The ‘Heart Outcomes Prevention
and Evaluation 4’ (HOPE-4) study aims to evaluate the effect
of a polypill based-treatment strategy (simvastatin 20 mg,
ramipril 5 mg, atenolol 50 mg and hydrochlorothiazide
12.5 mg) on major cardiovascular endpoints compared to usual
care in approximately 9500 participants aged 50 years and
older. Similarly, ‘The International Polycap Study 3’ (TIPS-3)
aims to evaluate the effect of the polycap in double strength
(simvastatin 40 mg, ramipril 10 mg, atenolol 100 mg and hy-
drochlorothiazide 25 mg), aspirin and cholecalciferol on major
cardiovascular events in 5500 participants at intermediate risk
aged 55 years and older in a factorial design. The results of both
trials are anticipated to become available by 2020.
As an alternative option for a licensed polypill-based treat-
ment strategy, alternatives have been marketed. In the early
2012, Wald and Law performed a randomized crossover trial
including 86 individuals aged older than 50 years. At baseline,
the systolic BP was 143 mmHg and the LDL cholesterol was
3.7 mmol/L. The participant received the polypill (simvastatin
40 mg, losartan 25 mg, amlodipine 2.5 mg and hydrochlorothi-
azide 12.5 mg) or placebo during a period of 12 weeks and
switched to the alternative treatment for another 12 weeks. The
use of the polypill resulted in a 17.9 mmHg (95 % CI 15.7 to
20.1) lower mean systolic BP and 1.4 mmol/L (95 % CI 1.2 to
1.6) lowermean LDL cholesterol. They suggested that long-term
reduction of this magnitude would have a substantial effect on
preventing cardiovascular disease [43].
Conclusion
Currently, BP-lowering therapy in hypertensive patients aims
to reduce the risk of cardiovascular disease. The polypill could
be an important tool to reduce the risk of cardiovascular disease
by simultaneously treat multiple risk factors and not exclusive-
ly hypertension. Data indicate that combination pills can pro-
duce sizeable risk factor reductions and increase long-term ad-
herence to therapy. Overall, a polypill is preferred by patients
over separate pills and the therapy is low-cost. Results from
ongoing trials that are further assessing the effectiveness of
combination pills in reducing BP levels and cholesterol and
the effects on adherence to indicated medications and clinical
outcomes would provide clear evidence on the role of polypill-
based treatment strategy on the long run. It would also hold
implications for policy-making to address both primary and
secondary cardiovascular preventions globally.
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